CVS rises after UBS upgrades on healthcare benefits recovery

** Brokerage UBS upgrades healthcare conglomerate CVS Health CVS.N to "buy" from "neutral," raising PT to $79 from $67

** New PT represents a ~13.2% upside to the stock's last close

** Shares of CVS up 2.2% at $70.1 premarket

** UBS says CVS has managed its Medicare Advantage plans well, giving the brokerage more confidence in its future performance

** UBS believes CVS will reduce its debt by late 2026, allowing for more share buybacks and further earnings growth

** UBS says it does not expect any major negative changes from drug pricing rules or its Star ratings in the near term

** As of last close, CVS stock up 52.8% YTD